Whole-genome sequencing to control antimicrobial resistance

被引:212
作者
Koeser, Claudio U. [1 ]
Ellington, Matthew J. [2 ]
Peacock, Sharon J. [1 ,2 ,3 ,4 ]
机构
[1] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England
[2] Publ Hlth England, Clin Microbiol & Publ Hlth Lab, Cambridge, England
[3] Cambridge Univ Hosp Natl Hlth Serv Fdn Trust, Cambridge, England
[4] Wellcome Trust Sanger Inst, Hinxton, England
基金
英国惠康基金;
关键词
whole-genome sequencing; antibiotic resistance; surveillance; diagnostics; MYCOBACTERIUM-TUBERCULOSIS COMPLEX; STAPHYLOCOCCUS-AUREUS; ANTIBIOTIC-RESISTANCE; ISONIAZID RESISTANCE; GENETIC DIVERSITY; MOLECULAR METHODS; ESCHERICHIA-COLI; DRUG-RESISTANCE; SUSCEPTIBILITY; EVOLUTION;
D O I
10.1016/j.tig.2014.07.003
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Following recent improvements in sequencing technologies, whole-genome sequencing (WGS) is positioned to become an essential tool in the control of antibiotic resistance, a major threat in modern healthcare. WGS has already found numerous applications in this area, ranging from the development of novel antibiotics and diagnostic tests through to antibiotic stewardship of currently available drugs via surveillance and the elucidation of the factors that allow the emergence and persistence of resistance. Numerous proof-of-principle studies have also highlighted the value of WGS as a tool for day-to-day infection control and, for some pathogens, as a primary diagnostic tool to detect antibiotic resistance. However, appropriate data analysis platforms will need to be developed before routine WGS can be introduced on a large scale.
引用
收藏
页码:401 / 407
页数:7
相关论文
共 100 条
  • [1] Aarestrup Frank M, 2012, Emerg Infect Dis, V18, pe1, DOI 10.3201/eid/1811.120453
  • [2] Gene Sequencing for Routine Verification of Pyrazinamide Resistance in Mycobacterium tuberculosis: a Role for pncA but Not rpsA
    Alexander, David C.
    Ma, Jennifer H.
    Guthrie, Jennifer L.
    Blair, Joanne
    Chedore, Pam
    Jamieson, Frances B.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (11) : 3726 - 3728
  • [3] A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis
    Ando, Hiroki
    Miyoshi-Akiyama, Tohru
    Watanabe, Shinya
    Kirikae, Teruo
    [J]. MOLECULAR MICROBIOLOGY, 2014, 91 (03) : 538 - 547
  • [4] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
    Andries, K
    Verhasselt, P
    Guillemont, J
    Göhlmann, HWH
    Neefs, JM
    Winkler, H
    Van Gestel, J
    Timmerman, P
    Zhu, M
    Lee, E
    Williams, P
    de Chaffoy, D
    Huitric, E
    Hoffner, S
    Cambau, E
    Truffot-Pernot, C
    Lounis, N
    Jarlier, V
    [J]. SCIENCE, 2005, 307 (5707) : 223 - 227
  • [5] Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis
    Angeby, Kristian
    Jureen, Pontus
    Kahlmeter, Gunnar
    Hoffner, Sven E.
    Schon, Thomas
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2012, 90 (09) : 693 - 698
  • [6] [Anonymous], CLOSTRIDIUM DIFFICIL
  • [7] [Anonymous], EVOL THREAT ANT RES
  • [8] [Anonymous], TUBERCULOSIS UK 2013
  • [9] [Anonymous], MYC ABSC SUGG INF PR
  • [10] [Anonymous], COLL TUB STRAT ENGL